HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
HHT drug trial pulled before it even started
Disease control TerminatedThis was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn bef…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to stop nosebleeds in rare genetic disorder
Disease control OngoingThis study tests a new drug called VAD044 in 75 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and anemia. The first part compares two doses of VAD044 against a placebo to see if it safely reduces the number, length, and sever…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Phase: PHASE1, PHASE2 • Sponsor: Vaderis Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can a cancer drug tame rare bleeding Disorder's heart complications?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether the drug bevacizumab can help people with a rare condition called hereditary hemorrhagic telangiectasia (HHT) who have severe liver problems leading to high heart output and possible heart failure. Researchers will check heart function before and after…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
HHT nosebleed drug shows promise in long-term follow-up study
Disease control OngoingThis study follows 62 adults with hereditary hemorrhagic telangiectasia (HHT) who previously took pomalidomide in a clinical trial. Researchers want to see if the drug safely reduces nosebleed severity and the need for iron or blood transfusions over time. Participants take pomal…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC